% 0期刊文章%西摩尼Avansini %一个法比奥·托雷斯%法比奥Rogerio % Danyella Dogini %安娜科安%罗德里戈Secolin %克莉斯婷罗查%一个安娜科斯塔%安德烈·科斯塔%一个安娜Piaza % Luzia举行泰德Reis % Evandro奥利维拉% %一个费尔南多Cendes卢西亚诺·奎罗斯% %一个Iscia Lopes-Cendes % T调查小分子核糖核酸的角色发展的监管局灶性皮质发育不良(P05.081) % D J神经病学2012% % P P05.081-P05.081 % V 78% N 1补充% X目的:调查可能的microrna的监管作用焦点皮质发育不良的病因(FCD)。首页背景小分子核糖核酸(microrna)是小非编码rna调节转录后基因表达。FCD是皮质的畸形发展,影响到36%的癫痫患者耐药。设计/方法:我们使用脑组织获得手术后治疗顽固性癫痫患者从9 FCD FCD IIa患者(4和5 FCD IIb型)患者。此外,我们使用从解剖皮质组织作为控制(n = 5)。总RNA分离与RecoverAllTM工具包(Ambion)和RNA完整性评估了安捷伦RNA Pico芯片工具包和Bio-Analyzer 2100。microrna的表达谱进行Affymetrix GeneChip平台microrna的数组。背景校正、总结和标准化是由RMA函数。microrna的表达进行了分析使用RankProd(罗斯福p < 0.05)。结果:我们初步分析确定23个差异表达microrna当病人和对照组比较。此外,当FCD IIa FCD IIb型组相比,我们发现6个差异表达microrna的类型。其中我们观察到显著下调几个元素属于mir - 17∼92集群。 This cluster is known to contribute to transcriptional regulation of stem cell differentiation, aging, as well as fine-tuning of pathways involved in neuronal differentiation.Conclusions: Thus our results clearly show that neurodevelopment pathways are indeed involved in the pathophysiology of FCD. In addition, we identified a different miRNA expression signature in different FCD histological subtypes.Supported by: Capes and Fapesp.Disclosure: Dr. Avansini has nothing to disclose. Dr. Torres has nothing to disclose. Dr. Rogério has nothing to disclose. Dr. Dogini has nothing to disclose. Dr. Coan has nothing to disclose. Dr. Secolin has nothing to disclose. Dr. Rocha has nothing to disclose. Dr. Costa has nothing to disclose. Dr. Costa has nothing to disclose. Dr. Piaza has nothing to disclose. Dr. Reis has nothing to disclose. Dr. Oliveira has nothing to disclose. Dr. Tedeschi has nothing to disclose. Dr. Queiroz has nothing to disclose. Dr. Cendes has nothing to disclose. Dr. Lopes-Cendes has nothing to disclose. Wednesday, April 25 2012, 14:00 pm-19:00 pm %U